Laurie Toich, Assistant Editor

Financial rewards may be an effective way to get young patients with diabetes to achieve blood glucose targets.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

New policies can help increase flexibility to improve Medicaid.

Adalimumab-adbm (Cyltezo) showed equivalent safety and immunogenicity to adalimumab (Humira).

Inhibiting a protein may reduce symptoms of diabetic retinopathy.

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

Growing evidence suggests immune deficiencies in the central nervous system are involved with Alzheimer’s disease.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Biosimilars have yet to make a significant impact on the prescription drug market.

FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.

A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.

Changes to the rules are expected to reduce physician burden and foster innovation in healthcare.

With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.

Mortality related to liver cirrhosis outpaces the rate for lung, colorectal, stomach, liver, and breast cancers.

Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.

New findings may result in a better treatment against Parkinson’s disease.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Alectinib (Alecensa) found to significantly improve progression-free survival among patients with lung cancer.

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer.

Some pharma executives welcome a disruption to the current pharmacy benefits management system.

Amazon entering pharmacy may transform pharmacy benefit managers.

Rigorous screening guidelines can reduce the number of undiagnosed cases of diabetes.

Only 1% of women aged 20 to 68 years had an oral HPV infection.

Vemurafenib is a kinase inhibitor indicated to treat patients with Erdheim-Chester disease with BRAF V600 mutations.

Vemurafenib (Zelboraf) receives priority review for Erdheim-Chester Disease.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.